舒利迭治疗COPD缓解期34例疗效观察

目的探讨舒利迭治疗慢性阻塞性肺疾病（COPD）缓解期的临床疗效。方法将68例住院COPD缓解期患者随机分为治疗组和对照组。对照组患者予以COPD常规治疗,包括低流量持续吸氧,预防感染,常规服用氨茶碱,增强机体免疫力,吸入异丙托溴铵,呼吸肌锻炼及按需使用沙丁胺醇。治疗组在对照组治疗的基础上加用舒利迭粉吸入剂,1吸/次,1次/d,每次2喷。两组患者疗程均为3个月。结果治疗组总有效率为88.24%,对照组总有效率为67.65%,两组总有效率比较差异有统计学意义（P〈0.05）。治疗后治疗组患者的用力肺活量（FVC）、第一秒用力呼气容积（FEV1）及FEV1/FVC均明显优于对照组,差异有统计学意义（P〈0.05）;治疗后治疗组患者的动脉血氧分压（PaO2）、二氧化碳分压（PaCO2）均明显优于对照组,差异有统计学意义（P〈0.05）。结论舒利迭吸入是COPD缓解期患者的一种有效、安全的治疗方法。

Observation of curative effects on Seretide in the treatment of 34 patients with chronic obstructive pulmonary disease of remission phase

Objective To investigate the curative effects of Seretide in the treatment of patients with chronic obstructive pulmonary disease(COPD) of remission phase.Methods 68 hospitalized patients in the COPD remission phase were randomly divided into treatment group and control group.The control group received COPD conventional treatment,including uptake of low-flow continuous oxygen,prevention of infection,routine administration of aminophylline,increase of body immunity,inhalation of ipratropium bromide,training of respiratory muscle and on-demand use of salbutamol.The treatment group received additional seretide powder inhalant 1 inhalation every time,once a day and 2 prays every time on the basis of conventional treatment.The treatment course for both groups was 3 months.Results The total effective rate was 88.24% in the treatment group and the total effective rate was 67.65% in the control group,with statistically significant difference between the two groups(P < 0.05).After treatment,the treatment group was superior to the control group in forced vital capacity(FVC),forced expiratory volume in 1 second(FEV1) and FEV1/FVC,with statistically significant differences(P < 0.05).After treatment,the treatment group was superior to the control group in PaO2 and PaCO2,with statistically significant differences(P < 0.05).Conclusion Seretide inhalation is a safe and effective therapy for patients in the COPD remission phase.